Joint Formulary & PAD

Ruxolitinib - Graft versus Host Disease (GVHD)

You are here : Home > Formulary Search > Ruxolitinib - Graft versus Host Disease (GVHD)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NFD2
NICE
SPC
Restrictions / Comments :
Important

TERMINATED NICE APPRAISAL

Documentation

NICE Technology Appraisal
NICE TA1132 - Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal) - February 2026

PAD Profile

ChemicalSubstance :
Ruxolitinib
Indication :
Graft versus Host Disease (GVHD)
Group Name :
Keywords :
Allogeneic Stem Cell transplant, children and young people, CYP
Brand Names Include :
Jakavi
Important Information :
Latest Additions Date From :
06 Mar 2026
Latest Additions Date To :
03 Apr 2026
Guidelines :
Supporting Documents :
1

Committee Recommendations (1)

04 Mar 26 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

This drug has not been assessed for formulary status.

NICE is unable to make a recommendation because the company has not provided an evidence submission. As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug it is recommended that clinicians contact their formulary team to discuss possible alternatives/options

Other Indications

Below are listed other indications that Ruxolitinib is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Graft versus Host Disease (GVHD).